Form 4 KALOBIOS PHARMACEUTICALS For: Nov 20 Filed by: Shkreli Martin
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St futures rise as AI stocks rally, crude prices fall
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Crypto stocks rise premarket as Bitcoin hits over seven-month high
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Streamflation drives 39% of Americans to cancel streaming in 6 months
- FortuneX and WT Realty announce $600M merger deal
KaloBios Pharma (KBIO) Could Drop 50% By Early Next Week: Tim Sykes
November 24, 2015 12:46 PM ESTTim Sykes thinks KaloBios Pharma (NASDAQ: KBIO) could drop 50% by early next week, according to the New York... More
KaloBios Pharma (KBIO) Receives NASDAQ Delisting Notice
November 23, 2015 5:46 PM ESTThe NASDAQ Stock Market notified KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO), by letter dated November 17, 2015, that the Company is not currently in compliance with Nasdaqs continued listing requirement set forth in Rule 5250(c)(1) of the Nasdaq Listing Rules (the Rules), due to its failure to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2015 (the 2015 Third Quarter 10-Q) with the Securities and Exchange Commission (the SEC).
Under the Rules, the Company has 60 calendar days from November 17, 2015 to submit a plan to Nasdaq to regain compliance with the Rules. The Company intends to file... More
KaloBios Pharma (KBIO) CEO Shkreli Purchased 5,000 Shares
November 23, 2015 3:12 PM ESTKaloBios Pharma (NASDAQ: KBIO) CEO Martin Shkreli disclosed a recent stock purchase.
In a Form 4 filing made today, Shkreli purchased 5,000 shares of the company's stock on November 20th for $18.88 per share.
The filing is embedded below:
... More